[1] Albagoush SA, Shumway C, Azevedo AM.Multiple Myeloma[M]. Stat Pearls Publishing LLC, 2024.
[2] Sanchez L, Barley K, Richter J, et al.Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review[J]. Expert Rev Hematol, 2020, 13(9): 943-958.
[3] Zheng Z, Wang L, Cheng S, et al.Autophagy and Myeloma[J]. Adv Exp Med Biol, 2020, 1207: 625-631.
[4] Bashiri H, Tabatabaeian H.Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma[J]. Int J Mol Sci, 2023, 24(7):6019.
[5] Wang L, Klionsky DJ, Shen HM.The emerging mechanisms and functions of microautophagy[J]. Nat Rev Mol Cell Biol, 2023, 24(3): 186-203.
[6] Liu Y, Tan L, Tan MS.Chaperone-mediated autophagy in neurodegenerative diseases: mechanisms and therapy[J]. Mol Cell Biochem, 2023, 478(10): 2173-2190.
[7] Bhat P, Kriel J, Priya BS, et al.Modulating autophagy in cancer therapy: Advancements and challenges for cancer cell death sensitization[J]. Biochem Pharmacol, 2018, 147: 170-182.
[8] Hamedi KR, Harmon KA, Goodwin RL, et al.Autophagy and the Bone Marrow Microenvironment: A Review of Protective Factors in the Development and Maintenance of Multiple Myeloma[J]. Front Immunol, 2022, 13: 889954.
[9] Ho M, Patel A, Hanley C, et al.Exploiting autophagy in multiple myeloma[J]. Journal of Cancer Metastasis and Treatment, 2019. Doi:10.20517/2394-4722.2019.25.
[10] Wolska-Washer A, Smolewski P.Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies[J]. Cancers (Basel), 2022, 14(15):3778.
[11] Yun Z, Zhichao J, Hao Y, et al.Targeting autophagy in multiple myeloma[J]. Leuk Res, 2017, 59: 97-104.
[12] Harmon KA, Roman S, Lancaster HD, et al.Structural and Ultrastructural Analysis of the Multiple Myeloma Cell Niche and a Patient-Specific Model of Plasma Cell Dysfunction[J]. Microsc Microanal, 2022, 28(1): 254-264.
[13] Yang BQ, Chen JM, Zeng ZY.Research Progress on Regulating Autophagy in the Treatment of Multiple Myeloma -Review[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2020, 28(2): 700-703.
[14] 罗国平,刘芬,谷文,等. 褐藻糖胶对U266细胞自噬、迁移及侵袭的影响[J]. 上海交通大学学报(医学版),2017,37(3): 312-317.
[15] Mateos MV, Weisel K, De Stefano V, et al.LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma[J]. Leukemia, 2022, 36(5): 1371-1376.
[16] 王亚茹,马艳萍. 多发性骨髓瘤硼替佐米耐药机制的研究进展[J]. 中国实验血液学杂志,2023,31(5): 1584-1587.
[17] Ramos A, Sadeghi S, Tabatabaeian H.Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them[J]. Int J Mol Sci, 2021, 22(17):9451.
[18] Wu J, Liu J.Research progress in proteasome inhibitor resistance to multiple myeloma[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2021, 46(8): 900-908.
[19] Jaganathan S, Malek E, Vallabhapurapu S, et al.Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells[J]. Oncotarget, 2014, 5(23): 12358-12370.
[20] Li Y, Xie J, Li X, et al.Poly (ADP-ribosylation) of HMGB1 facilitates its acetylation and promotes HMGB1 translocation-associated chemotherapy-induced autophagy in leukaemia cells[J]. Oncol Lett, 2020, 19(1): 368-378.
[21] Frassanito MA, De Veirman K, Desantis V, et al.Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients[J]. Leukemia, 2016, 30(3): 640-648.
[22] Xia J, He Y, Meng B, et al.NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma[J]. Mol Oncol, 2020, 14(4): 763-778.
[23] Shi MY, Yao Y, Deng J, et al.The Inhibiting Effect of Autophagy Inhibitor ROC-325 on Multiple Myeloma[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2021, 29(3): 797-804.
[24] 杨炳钦,陈君敏,曾志勇. 调节自噬治疗多发性骨髓瘤的研究进展[J]. 中国实验血液学杂志,2020, 28(2): 700-703.
[25] Moriya S, Kazama H, Hino H, et al.Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression[J]. PLoS One, 2023, 18(12): e0295273.
[26] Ikeda S, Abe F, Matsuda Y, et al.Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma[J]. Cancer Sci, 2020, 111(11): 4088-4101.
[27] Salimi A, Schroeder KM, Schemionek-Reinders M, et al.Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK[J]. BMC Cancer, 2022, 22(1): 735.
[28] Galluzzi L, Baehrecke EH, Ballabio A, et al.Molecular definitions of autophagy and related processes[J]. Embo J, 2017, 36(13): 1811-1836.
[29] Wang JZ, Chen JM, Zeng ZY, et al.Effects of Autophagy Regulating Drugs on Proliferation, Apoptosis and Autophagy of Multiple Myeloma Cells[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2018, 26(3): 817-823.
[30] Lamy L, Ngo VN, Emre NC, et al.Control of autophagic cell death by caspase-10 in multiple myeloma[J]. Cancer Cell, 2013, 23(4): 435-449.
[31] 王盼盼,朱登勤,杨晓煜. 多发性骨髓瘤发病机制及治疗的研究进展[J]. 中国医学创新,2023, 20(13): 164-168.
[32] 千晨静,洪梅,夏凌辉. 多发性骨髓瘤新型治疗方案的研究进展[J]. 肿瘤防治研究,2023,50(3): 321-325.
[33] Kozalak G, Koşar A.Autophagy-related mechanisms for treatment of multiple myeloma[J]. Cancer Drug Resist, 2023, 6: 838-857.
[34] Al-Odat OS, Guirguis DA, Schmalbach NK, et al.Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma[J]. Int J Mol Sci, 2022, 24(1):644.
[35] Pinto V, Bergantim R, Caires HR, et al.Multiple Myeloma: Available Therapies and Causes of Drug Resistance[J]. Cancers (Basel), 2020, 12(2):407.
[36] Morel E, Mehrpour M, Botti J, et al.Autophagy: A Druggable Process[J]. Annu Rev Pharmacol Toxicol, 2017, 57: 375-398. |
